Literature DB >> 7642347

Chemoconvulsant seizures: advantages of focally-evoked seizure models.

K Gale1.   

Abstract

Studies of short and long-term changes in regional metabolism, blood flow, gene expression (including immediate early genes and genes for neurotrophic factors), sprouting and cell death following seizures are pivotal to an understanding of the neural networks responsible for the generation of seizures. At the same time, this information forms a basis for understanding the pathophysiology associated with chronic, recurrent seizures. Systemic chemoconvulsant seizure models, produced by systemically administered chemoconvulsant agents, although convenient, are plagued with difficulties which confound the interpretation of their effects on the nervous system. These difficulties include widespread direct cellular and physiological effects of the chemoconvulsant drugs, most of which are independent of seizures. In addition, numerous physiological changes occur as a secondary consequence of, or ancillary to, seizures, and it can be especially difficult to separate these effects from the direct effects of the propagated seizure discharge itself. Some of these difficulties can be overcome by the use of focally-evoked seizure models. Such models avoid the diffuse presence of drug throughout the CNS and thereby eliminate most of the direct cellular and physiologic actions of the drug apart from seizure-induction. Large regions of the brain distant from the focal site of drug application then can be examined for molecular, structural and physiologic changes uncomplicated by the presence of drug. Moreover, different focal sites of drug application can be compared to evaluate the specificity of the molecular changes to the neural network engaged in the seizure discharge. For example, limbic seizures, evoked by chemoconvulsant application into area tempestas, can be compared with brainstem convulsions evoked by chemoconvulsant application into inferior colliculus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7642347     DOI: 10.1007/bf02229070

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  38 in total

1.  Distribution of HSP72 induction and neuronal death following limbic seizures.

Authors:  S Shimosaka; Y T So; R P Simon
Journal:  Neurosci Lett       Date:  1992-04-27       Impact factor: 3.046

2.  Focal injection of 2-amino-7-phosphonoheptanoic acid into prepiriform cortex protects against pilocarpine-induced limbic seizures in rats.

Authors:  M H Millan; S Patel; L M Mello; B S Meldrum
Journal:  Neurosci Lett       Date:  1986-09-25       Impact factor: 3.046

3.  Presynaptic kainate and N-methyl-D-aspartate receptors regulate excitatory amino acid release in the olfactory cortex.

Authors:  G G Collins; J Anson; L Surtees
Journal:  Brain Res       Date:  1983-04-11       Impact factor: 3.252

4.  Short- and long-term induction of basic fibroblast growth factor gene expression in rat central nervous system following kainate injection.

Authors:  M A Riva; E Donati; F Tascedda; M Zolli; G Racagni
Journal:  Neuroscience       Date:  1994-03       Impact factor: 3.590

5.  c-Fos mRNA induction under vitamin B6 antagonist-induced seizure.

Authors:  A Mizuno; T Mizobuchi; Y Ishibashi; M Matsuda
Journal:  Neurosci Lett       Date:  1989-04-10       Impact factor: 3.046

6.  Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study.

Authors:  W A Turski; E A Cavalheiro; M Schwarz; S J Czuczwar; Z Kleinrok; L Turski
Journal:  Behav Brain Res       Date:  1983-09       Impact factor: 3.332

7.  Long-lasting and sequential increase of c-fos oncoprotein expression in kainic acid-induced status epilepticus.

Authors:  G Le Gal La Salle
Journal:  Neurosci Lett       Date:  1988-05-26       Impact factor: 3.046

8.  Microinjections of the gamma-aminobutyrate antagonist, bicuculline methiodide, into the caudate-putamen prevent amygdala-kindled seizures in rats.

Authors:  E A Cavalheiro; Z A Bortolotto; L Turski
Journal:  Brain Res       Date:  1987-05-19       Impact factor: 3.252

9.  Lesions of the deep prepiriform cortex ('area tempestas') in rats do not affect the convulsant action of systemically administered bicuculline.

Authors:  U Wahnschaffe; W Löscher
Journal:  Neurosci Lett       Date:  1990-01-01       Impact factor: 3.046

10.  Regional and temporal pattern of expression of nerve growth factor and basic fibroblast growth factor mRNA in rat brain following electroconvulsive shock.

Authors:  P Follesa; K Gale; I Mocchetti
Journal:  Exp Neurol       Date:  1994-05       Impact factor: 5.330

View more
  7 in total

1.  Pharmaco-resistant Neonatal Seizures: Critical Mechanistic Insights from a Chemoconvulsant Model.

Authors:  Shivani C Kharod; Brandon M Carter; Shilpa D Kadam
Journal:  Dev Neurobiol       Date:  2018-08-31       Impact factor: 3.964

2.  Epileptogenesis-induced changes of hippocampal-piriform connectivity.

Authors:  Mark D Skopin; Arezou Bayat; Lalitha Kurada; Mithilesh Siddu; Sweta Joshi; Christina M Zelano; Mohamad Z Koubeissi
Journal:  Seizure       Date:  2020-07-10       Impact factor: 3.184

Review 3.  Animal models relevant to human epilepsies.

Authors:  G Avanzini
Journal:  Ital J Neurol Sci       Date:  1995 Feb-Mar

Review 4.  Critical evaluation of animal models for localization-related epilepsies.

Authors:  J Engel
Journal:  Ital J Neurol Sci       Date:  1995 Feb-Mar

5.  Protection against sarin-induced seizures in rats by direct brain microinjection of scopolamine, midazolam or MK-801.

Authors:  Jacob W Skovira; John H McDonough; Tsung-Ming Shih
Journal:  J Mol Neurosci       Date:  2009-08-19       Impact factor: 3.444

6.  Converging PET and fMRI evidence for a common area involved in human focal epilepsies.

Authors:  H Laufs; M P Richardson; A Salek-Haddadi; C Vollmar; J S Duncan; K Gale; L Lemieux; W Löscher; M J Koepp
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

Review 7.  The piriform cortex and human focal epilepsy.

Authors:  David N Vaughan; Graeme D Jackson
Journal:  Front Neurol       Date:  2014-12-08       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.